A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Must have received: immunotherapy and targeted therapy

Part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.

Must have received: PD-1/PD-L1 inhibitor and VEGF-TKI

Part 2: Participants must have had at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other).

Must have received: PD-1/PD-L1 checkpoint inhibitor and/or VEGF-TKI

Part 3: Participants must have had at least 1 standard treatment regimen (including a PD-1/L1 checkpoint inhibitor and/or a VEGF-TKI).

Cannot have received: systemic therapy for metastatic RCC

Exception: prior adjuvant therapy for completely resected RCC with PD-1 inhibitor if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy

Part 4: Participants must not have received prior systemic therapy for metastatic RCC, but may have received prior adjuvant therapy for completely resected RCC with PD-1 inhibitor if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.

Cannot have received: systemic regimens for locally advanced or metastatic ccRCC including HIF2a inhibitors

Exception: more than 3 prior regimens

Part 2A: Participants who have received more than 3 prior systemic regimens for locally advanced or metastatic ccRCC including prior treatment with HIF2a inhibitors.

Cannot have received: HIF2a inhibitor (belzutifan)

Part 2A and Part 4: Participants who have received prior treatment with belzutifan (or another HIF2a inhibitor).

Cannot have received: anti-CTLA-4 containing antibody (ipilimumab)

Part 3B and Part 4B: Participants who have received prior ipilimumab (or another anti-CTLA-4 containing antibody).